106 related articles for article (PubMed ID: 32305266)
1. Development and evaluation of the MiCheck test for aggressive prostate cancer.
Shore ND; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Levin RA; Wissmueller S; Le TH; Gillatt D; Chan DW; Campbell DH; Walsh BJ
Urol Oncol; 2020 Aug; 38(8):683.e11-683.e18. PubMed ID: 32305266
[TBL] [Abstract][Full Text] [Related]
2. A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial.
Shore ND; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Le TH; Levin RA; Wissmueller S; Prah P; Borotkanics R; Paivanas TA; van Breda A; Campbell DH; Walsh BJ
Urol Oncol; 2020 Aug; 38(8):683.e1-683.e10. PubMed ID: 32360170
[TBL] [Abstract][Full Text] [Related]
3. Development and evaluation of the MiCheck® Prostate test for clinically significant prostate cancer.
Shore ND; Polikarpov DM; Pieczonka CM; Henderson RJ; Bailen JL; Saltzstein DR; Concepcion RS; Beebe-Dimmer JL; Ruterbusch JJ; Levin RA; Wissmueller S; Le TH; Gillatt DA; Chan DW; Deng N; Siddireddy JS; Lu Y; Campbell DH; Walsh BJ
Urol Oncol; 2023 Nov; 41(11):454.e9-454.e16. PubMed ID: 37734979
[TBL] [Abstract][Full Text] [Related]
4. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
5. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
6. Extended use of Prostate Health Index and percentage of [-2]pro-prostate-specific antigen in Chinese men with prostate specific antigen 10-20 ng/mL and normal digital rectal examination.
Chiu PK; Teoh JY; Lee WM; Yee CH; Chan ES; Hou SM; Ng CF
Investig Clin Urol; 2016 Sep; 57(5):336-42. PubMed ID: 27617315
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study.
Morote J; Celma A; Planas J; Placer J; Ferrer R; de Torres I; Pacciuci R; Olivan M
Actas Urol Esp; 2016; 40(6):378-85. PubMed ID: 26923032
[TBL] [Abstract][Full Text] [Related]
8. Developing a model for forecasting Gleason score ≥7 in potential prostate cancer patients to reduce unnecessary prostate biopsies.
Li X; Pan Y; Huang Y; Wang J; Zhang C; Wu J; Cheng G; Qin C; Hua L; Wang Z
Int Urol Nephrol; 2016 Apr; 48(4):535-40. PubMed ID: 26810323
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
Gosselaar C; Roobol MJ; Roemeling S; van der Kwast TH; Schröder FH
Prostate; 2007 Feb; 67(2):154-61. PubMed ID: 17044079
[TBL] [Abstract][Full Text] [Related]
10. Prostate Health Index (PHI) improves prostate cancer detection at initial biopsy in Taiwanese men with PSA 4-10 ng/mL.
Hsieh PF; Chang CH; Yang CR; Huang CP; Chen WC; Yeh CC; Chou EC; Chen KL; Lien CS; Chen GH; Hsiao PJ; Chang YH; Wu HC
Kaohsiung J Med Sci; 2018 Aug; 34(8):461-466. PubMed ID: 30041764
[TBL] [Abstract][Full Text] [Related]
11. Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Agostino J; Macura KJ; Carter HB; Schaeffer EM; Partin AW; Sokoll LJ; Ross AE
Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):228-233. PubMed ID: 28117387
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of [-2]propsa (p2psa) and its derivatives for the prostate cancer detection in the 2.0 to 10.0ng/mL PSA range.
Vukovic I; Djordjevic D; Bojanic N; Babic U; Soldatovic I
Int Braz J Urol; 2017; 43(1):48-56. PubMed ID: 28124526
[TBL] [Abstract][Full Text] [Related]
13. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.
Stephan C; Jung K; Semjonow A; Schulze-Forster K; Cammann H; Hu X; Meyer HA; Bögemann M; Miller K; Friedersdorff F
Clin Chem; 2013 Jan; 59(1):280-8. PubMed ID: 23213079
[TBL] [Abstract][Full Text] [Related]
14. Clinical usefulness of free PSA in early detection of prostate cancer.
Luboldt HJ; Swoboda A; Börgermann C; Fornara P; Rübben H;
Onkologie; 2001 Feb; 24(1):33-7. PubMed ID: 11441278
[TBL] [Abstract][Full Text] [Related]
15. Prostate Health Index density improves detection of clinically significant prostate cancer.
Tosoian JJ; Druskin SC; Andreas D; Mullane P; Chappidi M; Joo S; Ghabili K; Mamawala M; Agostino J; Carter HB; Partin AW; Sokoll LJ; Ross AE
BJU Int; 2017 Dec; 120(6):793-798. PubMed ID: 28058757
[TBL] [Abstract][Full Text] [Related]
16. Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study.
Lazzeri M; Lughezzani G; Haese A; McNicholas T; de la Taille A; Buffi NM; Cardone P; Hurle R; Casale P; Bini V; Redorta JP; Graefen M; Guazzoni G
Urol Oncol; 2016 Sep; 34(9):415.e13-9. PubMed ID: 27178729
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
[TBL] [Abstract][Full Text] [Related]
18. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
[TBL] [Abstract][Full Text] [Related]
19. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
[TBL] [Abstract][Full Text] [Related]
20. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
